Comparing Generic Drug Markets in Europe and the United States: Prices, Volumes, and Spending
Originally published by Er J. Wouters, Panos G. Kavanos, Martin McKee in The Milbank Quarterly, 95: 554–601 under a Creative Commons License. […]
Originally published by Er J. Wouters, Panos G. Kavanos, Martin McKee in The Milbank Quarterly, 95: 554–601 under a Creative Commons License. […]
This article was originally published by Ekaterina Galkina Cleary, Jennifer M. Beierlein, Navleen Surjit Khanuja, Laura M. McNamee and Fred D.
Contribution of NIH funding to new drug approvals 2010–2016 Read Post »
Without a strong biosimilars market, costs for biologics in the US continue trending upward. The world of drug patents for
Formularies come into effect at the hospital level and the individual insurer level When developed and managed with due care
Formulary Decisions: Exploring the Ethics of Drug Approval Read Post »
MAKE BETTER DECISIONS Join the 500+ leading biopharmaceutical companies we have served and make better decisions with DrugPatentWatch’s deep knowledge
Biosimilars have emerged as a promising solution to reduce healthcare costs and improve patient access to life-saving biologics. However, the
Top 5 Challenges Faced By Biosimilars: Navigating the Complex Landscape Read Post »
The biotechnology industry is at the forefront of scientific innovation, promising groundbreaking solutions to some of the world’s most pressing
This article was originally published by Christopher Southan, Peter Varkonyi, Kiran Boppana, Sarma A.R.P. Jagarlapudi, and Sorel Muresan at PLoS ONE
Tracking 20 Years of Compound-to-Target Output from Literature and Patents Read Post »
In the ever-evolving landscape of pharmaceutical research, a new player has emerged that’s shaking up the industry: Artificial Intelligence (AI).
Subscribe to our weekly newsletter below and never miss the latest product or an exclusive offer.